Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05733819 · ClinicalTrials.gov registry record · Phase 1

Responders to Rhythmic Auditory Cueing in Parkinson Disease

A Phase 1 study of Parkinson Disease, sponsored by Boston University Charles River Campus.

Completed
Registry status
Phase 1
Development phase
31
Enrollment target
1
Study location

NCT05733819: Completed Phase 1 study of Parkinson Disease, sponsored by Boston University Charles River Campus.

NCT05733819 is a Phase 1 study of Parkinson Disease that has completed, run by Boston University Charles River Campus. The registered enrollment target is 31 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05733819, a Phase 1 study of Parkinson Disease, has completed, sponsored by Boston University Charles River Campus.

COMPLETED
Registry status
Phase 1
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

Parkinson disease (PD) is the second most common neurodegenerative disease affecting approximately 10 million people worldwide. It is a complex movement disorder that results in reduced walking ability. Prior studies have identified declines in walking as a marker of ensuing disability. Rhythmic auditory stimulation (RAS) is a rehabilitation approach that employs the coupling of auditory cues with movement. Walking with RAS has been shown to benefit walking rhythmicity, quality, and speed. These walking benefits make RAS advantageous in promoting regular moderate-intensity walking activity -- an important health objective in the management of PD. However, there is limited research investigating the effects of RAS on walking quality and how improvements in walking speed are achieved. This study will enroll 30 individuals with mild to moderate PD where each participant will be asked to complete two six-minute walk tests, one standard test (baseline) and the other using an optimized metronome-based auditory cueing RAS intervention. The investigators hypothesize that individuals with PD will either walk farther or with more automaticity (i.e., reduced stride time variability) in the RAS condition compared to the baseline condition. Moreover, these walking improvements will be accompanied by improvements in gait mechanics and metabolic cost of walking.

Primary Outcome

difference in total distance walked with and without RAS. (m)

Conditions Studied

Interventions

  • DEVICE Subject-specific optimized RAS
  • BEHAVIORAL Active Walking

Study Locations (1)

Massachusetts

  • Boston University Neuromotor Recovery Laboratory - Boston

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2023-01-17
Est. Completion 2023-06-30
Phase Phase 1

What the finished NCT05733819 record still lists

NCT05733819 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Subject-specific optimized RAS is the first listed.

NCT05733819 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05733819 about?

NCT05733819 is a clinical study titled "Responders to Rhythmic Auditory Cueing in Parkinson Disease". Parkinson disease (PD) is the second most common neurodegenerative disease affecting approximately 10 million people worldwide. It is a complex movement disorder that results in reduced walking ability. Prior studies have identified declines in walking as a marker of ensuing disability. Rhythmic aud...

What is the current status of trial NCT05733819?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2023-01-17. Estimated completion is 2023-06-30.

What conditions does trial NCT05733819 study?

This clinical trial studies the following conditions: Parkinson Disease.

What interventions are being tested in trial NCT05733819?

The interventions under investigation include: Subject-specific optimized RAS (DEVICE), Active Walking (BEHAVIORAL).

Who is sponsoring clinical trial NCT05733819?

This trial is sponsored by Boston University Charles River Campus, which has 104 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05733819 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05733819's enrollment target sits among peer trials

31 205th of 297 higher than 90 of 297 other Parkinson Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02932618 · 31 participants · Phase 3

    A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

  • NCT03482297 · 31 participants · Phase 1

    Automated Abdominal Binder for Orthostatic Hypotension

  • NCT04016389 · 31 participants · NA

    FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

  • NCT04211675 · 31 participants · Phase 1

    NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05733819, the US trial registry maintained by the National Library of Medicine. NCT05733819 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.